Clinical trials: Schizophrenia
Schizophrenia
Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (P06238)
This is a multi-site, open-label fixed-flexible dose long-term study of asenapine in participants with schizophrenia. Participants in this study consist of schizophrenia with residual subtype or receiving high dose/multiple…
- Trial name
- NCT01244828
- Testing
- Asenapine
- Volunteers
- 157 people
- Sponsor
- Organon and Co
Schizophrenia
Study to Evaluate Safety & Efficacy of NaBen® as Add-on Treatment for Schizophrenia in Adults
The proposed Phase IIb/III study is designed to evaluate the safety and efficacy of NaBen® in improving the symptoms of schizophrenia in adults.
- Trial name
- NCT02261519
- Testing
- NaBen®
- Where
- United States
- Volunteers
- 280 people
- Sponsor
- SyneuRx International (Taiwan) Corp
Schizophrenia, Bipolar I Disorder
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1)
This study is an open label, sequential-group, two site, multiple dose escalating study of sublingual administered asenapine in a pediatric population with schizophrenia or bipolar I disorder; in one study cohort (3a)…
- Trial name
- NCT01206517
- Testing
- Asenapine 2.5 mg, Asenapine 5 mg, Asenapine 10 mg
- Volunteers
- 30 people
- Sponsor
- Organon and Co
Schizophrenia, Schizophreniform Disorders
Benefits of Combining MCT With CR in the Recovery of Patients With Psychotic Spectrum Disorders
The goal of this clinical trial is to compare the efficacy of combined REHACOP + MCT alone in persons with nonaffective psychotic disorder in terms of recovery.
- Conditions
- Schizophrenia, Schizophreniform Disorders, Delusional Disorder, Brief Psychotic Disorder
- Trial name
- CR+MCTp (NCT06423651)
- Testing
- Cognitive Remediation (REHACOP), Metacognitive Training (MCT)
- Where
- Spain
- Volunteers
- 160 people
- Sponsor
- Universitat Autonoma de Barcelona
Schizophrenia, Paranoid, Schizophrenia, Disorganized
Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05897)
This study is designed to evaluate whether asenapine, which is approved by the United States Food and Drug Administration (US FDA) for acute treatment of schizophrenia in adults, is generally safe and well tolerated in…
- Conditions
- Schizophrenia, Paranoid, Schizophrenia, Disorganized, Schizophrenia, Undifferentiated
- Trial name
- NCT01190267
- Testing
- asenapine
- Volunteers
- 204 people
- Sponsor
- Organon and Co
Schizophrenia, Paranoid, Schizophrenia, Disorganized
Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896)
This study is designed to evaluate whether asenapine, which is approved by the United States Food and Drug Administration (US FDA) for acute treatment of schizophrenia in adults, is also effective in adolescents with…
- Conditions
- Schizophrenia, Paranoid, Schizophrenia, Disorganized, Schizophrenia, Undifferentiated
- Trial name
- NCT01190254
- Testing
- asenapine 2.5 mg, asenapine 5.0 mg
- Volunteers
- 306 people
- Sponsor
- Organon and Co
Schizophrenia, Schizophreniform Disorders
Individual Placement and Support and/or Cognitive Remediation Therapy Added to TAU in Patients With Early Schizophrenia
This study aims to test the hypothesis that addition of Individual Placement and Support (IPS) and/or Cognitive Remediation Therapy (CRT) in addition to treatment as usual in patients with early psychosis will be feasible and…
- Conditions
- Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorder, Psychosis
- Trial name
- NCT03974620
- Testing
- Individual Placement and Support, Cognitive Remediation Therapy
- Volunteers
- 120 people
- Sponsor
- Pakistan Institute of Living and Learning
Schizophrenia
Brain Stimulation, Clinical Symptoms and Cognition
The purpose of this study is to test the impact of non-invasive brain stimulation, transcranial direct current stimulation (tDCS), on auditory hallucinations, negative symptoms and cognition in schizophrenia.
- Trial name
- NCT05053451
- Testing
- Transcranial Direct Current Stimulation
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Schizophrenia, Schizoaffective Disorder
The Efficacy of Metacognitive Skills Training in the Context of Forensic Psychiatric Care
Deficiencies in social cognition are part of the core symptomatology of psychotic disorders. And deficiencies in social cognition, the closely related concept of metacognition, and, for example, paranoid attitudes are all…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Psychotic Disorders, Delusional Disorder
- Trial name
- NCT06005766
- Testing
- Metacognitive Skills Training (MCT), Treatment as usual
- Where
- Finland
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- University of Jyvaskyla
Schizophrenia
Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®
The purpose of this study is to determine if NaBen® is a safe and effective add-on treatment for schizophrenia in adolescents.
- Trial name
- NCT01908192
- Testing
- NaBen®
- Where
- 23 sites in United States, Taiwan
- Volunteers
- 60 people
- Sponsor
- SyneuRx International (Taiwan) Corp
Schizophrenia and Related Disorders, Diet Habit
Efficacy of Prebiotic and Probiotic Dietary Modulation in Schizophrenic Disorders
The microbiota plays a vital role in the two-way communication between the gastrointestinal tract and the central nervous system (CNS), articulated as the microbiota-intestine-brain axis.
- Trial name
- NCT04366401
- Testing
- Conventional Dietary Advice, Prebiotic/Probiotic Dietary Modulation
- Where
- Spain
- Volunteers
- 44 people
- Sponsor
- Universidad de Córdoba
Schizophrenia, Schizo Affective Disorder
Brain Stimulation and Cognitive Training - Efficacy
People with serious mental illness often experience difficulties with thinking skills like memory. These difficulties can make it harder to perform day-to-day activities.
- Conditions
- Schizophrenia, Schizo Affective Disorder, Bipolar Disorder
- Trial name
- NCT05111548
- Testing
- tDCS (Active), BrainHQ, tDCS (Inactive)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Michigan
Smoking, Schizophrenia Spectrum and Other Psychotic Disorders
Cigarette Consumption After switchinG to High or Low Nicotine strENght E-cigaretteS In Smokers With Schizophrenia
Smokers with schizophrenia spectrum disorders have high rates of morbidity and mortality from smoking-related diseases compared with the general population and current options for smoking cessation in this vulnerable group are…
- Trial name
- GENESIS (NCT04452175)
- Testing
- JUUL E-CIGARETTE
- Where
- Italy
- Volunteers
- 260 people
- Sponsor
- University of Catania
Psychosis, Schizophrenia
Goals in Focus: CBT for Motivational Negative Symptoms of Psychosis
This pilot feasibility trial aims to evaluate the "Goals in Focus" intervention for motivational negative symptoms in people with psychosis.
- Conditions
- Psychosis, Schizophrenia, Negative Symptoms With Primary Psychotic Disorder
- Trial name
- GIF (NCT05252039)
- Testing
- Goals in Focus
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- University of Hamburg-Eppendorf
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Schizophrenia Spectrum and Other Psychotic Disorders
Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia
Schizophrenia (SZ) is a highly debilitating neuropsychiatric disorder of young adulthood onset and a leading cause of disability worldwide.
- Trial name
- NCT03323437
- Testing
- Risperidone
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Schizophrenia
Impact of Inflammation on Reward Circuits, Motivational Deficits and Negative Symptoms in Schizophrenia
This study will recruit persons with schizophrenia or schizoaffective disorder and will use an oral glucose tolerance test to test the hypothesis that insulin resistance drives inflammation.
- Trial name
- NCT03818516
- Testing
- Oral Glucose Tolerance Test (OGTT)
- Where
- 6 sites in United States
- Volunteers
- 12 people
- Sponsor
- Emory University
Schizophrenia, Schizoaffective Disorder
Comparative Effectiveness of Adaptive Treatment Strategies for Schizophrenia
The study is a retrospective cohort study of adults with schizophrenia that will compare outcomes of new users of alternative psychotropic medication strategies using 10 years of Medicaid data.
- Trial name
- NCT02775864
- Testing
- Antipsychotic, Antidepressant, Benzodiazepine
- Volunteers
- 81,921 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia
Evaluation of Tolcapone as a Cognitive Enhancer in Schizophrenia
Objective: To assess the efficacy of tolcapone to improve cognition in schizophrenia, as a genotype-based targeted treatment of cognitive and negative symptoms of schizophrenia considering the polymorphism rs4680.
- Trial name
- NCT06387771
- Testing
- Tolcapone
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis
A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017
This is a phase 1，randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability and pharmacokinetics of oral LPM526000133 Fumarate Capsules (LY03017) in healthy adult subjects.
- Conditions
- Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia
- Trial name
- NCT06388551
- Testing
- LY03017
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.